drugset
drugset / Trial / NCT06297629

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

NCT06297629 ↗

Phase 2 Withdrawn M.D. Anderson Cancer Center Astex Pharmaceuticals, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To learn if ASTX727 given alone or in combination with donor lymphocyte infusion (DLI) can help to control certain types of hematological neoplasms (blood-based cancers) after a stem cell transplant.

Timeline

Start
2024-07-01
Primary completion
2024-07-11
Completion
2024-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ASTX727 Unknown — Oral

Indications

disease related to hematopoietic stem cell transplant